Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1969 1
1972 2
1974 1
1975 2
1976 1
1977 3
1979 1
1980 1
1981 1
1982 1
1983 2
1984 2
1985 1
1986 1
1987 1
1990 1
1998 1
2001 1
2003 2
2004 3
2005 2
2006 2
2007 4
2009 7
2010 7
2011 7
2012 6
2013 2
2014 4
2015 5
2016 2
2017 2
2018 3
2019 2
2020 8
2021 10
2022 1
2023 5
2024 2
2025 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

102 results

Results by year

Filters applied: . Clear all
Page 1
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, Bellamy D, Bibi S, Bittaye M, Clutterbuck EA, Dold C, Faust SN, Finn A, Flaxman AL, Hallis B, Heath P, Jenkin D, Lazarus R, Makinson R, Minassian AM, Pollock KM, Ramasamy M, Robinson H, Snape M, Tarrant R, Voysey M, Green C, Douglas AD, Hill AVS, Lambe T, Gilbert SC, Pollard AJ; Oxford COVID Vaccine Trial Group. Folegatti PM, et al. Lancet. 2020 Aug 15;396(10249):467-478. doi: 10.1016/S0140-6736(20)31604-4. Epub 2020 Jul 20. Lancet. 2020. PMID: 32702298 Free PMC article. Clinical Trial.
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.
Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE, Bibi S, Briner C, Cicconi P, Collins AM, Colin-Jones R, Cutland CL, Darton TC, Dheda K, Duncan CJA, Emary KRW, Ewer KJ, Fairlie L, Faust SN, Feng S, Ferreira DM, Finn A, Goodman AL, Green CM, Green CA, Heath PT, Hill C, Hill H, Hirsch I, Hodgson SHC, Izu A, Jackson S, Jenkin D, Joe CCD, Kerridge S, Koen A, Kwatra G, Lazarus R, Lawrie AM, Lelliott A, Libri V, Lillie PJ, Mallory R, Mendes AVA, Milan EP, Minassian AM, McGregor A, Morrison H, Mujadidi YF, Nana A, O'Reilly PJ, Padayachee SD, Pittella A, Plested E, Pollock KM, Ramasamy MN, Rhead S, Schwarzbold AV, Singh N, Smith A, Song R, Snape MD, Sprinz E, Sutherland RK, Tarrant R, Thomson EC, Török ME, Toshner M, Turner DPJ, Vekemans J, Villafana TL, Watson MEE, Williams CJ, Douglas AD, Hill AVS, Lambe T, Gilbert SC, Pollard AJ; Oxford COVID Vaccine Trial Group. Voysey M, et al. Lancet. 2021 Jan 9;397(10269):99-111. doi: 10.1016/S0140-6736(20)32661-1. Epub 2020 Dec 8. Lancet. 2021. PMID: 33306989 Free PMC article. Clinical Trial.
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002).
Flaxman A, Marchevsky NG, Jenkin D, Aboagye J, Aley PK, Angus B, Belij-Rammerstorfer S, Bibi S, Bittaye M, Cappuccini F, Cicconi P, Clutterbuck EA, Davies S, Dejnirattisai W, Dold C, Ewer KJ, Folegatti PM, Fowler J, Hill AVS, Kerridge S, Minassian AM, Mongkolsapaya J, Mujadidi YF, Plested E, Ramasamy MN, Robinson H, Sanders H, Sheehan E, Smith H, Snape MD, Song R, Woods D, Screaton G, Gilbert SC, Voysey M, Pollard AJ, Lambe T; Oxford COVID Vaccine Trial group. Flaxman A, et al. Lancet. 2021 Sep 11;398(10304):981-990. doi: 10.1016/S0140-6736(21)01699-8. Epub 2021 Sep 1. Lancet. 2021. PMID: 34480858 Free PMC article.
[Staging of aniridia-associated keratopathy].
Náray A, Fries FN, Csidey M, Kéki-Kovács K, Németh O, Knézy K, Bausz M, Szigeti A, Csorba A, Kormányos K, Szabó D, Corton M, Tory K, Nagy ZZ, Maka E, Szentmáry N. Náray A, et al. Among authors: szigeti a. Orv Hetil. 2023 Jul 9;164(27):1063-1069. doi: 10.1556/650.2023.32803. Print 2023 Jul 9. Orv Hetil. 2023. PMID: 37422887 Hungarian.
[Congenital aniridia - Hungarian data of a spectrum disease].
Náray A, Csidey M, Kéki-Kovács K, Németh O, Knézy K, Bausz M, Szigeti A, Csorba A, Kormányos K, Szabó D, Stachon T, Corton M, Tory K, Nagy ZZ, Maka E, Szentmáry N. Náray A, et al. Among authors: szigeti a. Orv Hetil. 2023 Jan 29;164(4):148-155. doi: 10.1556/650.2023.32697. Print 2023 Jan 29. Orv Hetil. 2023. PMID: 36709437 Hungarian.
Improved survival of non-small cell lung cancer patients after introducing patient navigation: A retrospective cohort study with propensity score weighted historic control.
Pitter JG, Moizs M, Ezer ÉS, Lukács G, Szigeti A, Repa I, Csanádi M, Rutten-van Mölken MPMH, Islam K, Kaló Z, Vokó Z. Pitter JG, et al. Among authors: szigeti a. PLoS One. 2022 Oct 25;17(10):e0276719. doi: 10.1371/journal.pone.0276719. eCollection 2022. PLoS One. 2022. PMID: 36282840 Free PMC article.
102 results